Amer Zeidan, Associate Professor of Medicine (Hematology) at Yale University, posted on X:

“The entire MDS is anxiously waiting for the results of the randomized Phase 3 VERONA trial of azacitidine + venetoclax versus azacitidine-+Placebo in patients with higher risk MDS with the primary endpoint of overall survival, what do you expect the results to be?”

Amer Zeidan invited responses on expectations for the VERONA trial results in higher-risk MDS patients. He offered four answer options: positive, negative, too close to guess, or I don’t manage MDS.

Amer Zeidan Reflects on Anticipation for VERONA Trial Results in High-Risk MDS

“The entire MDS is anxiously waiting for the results of the randomized Phase 3 VERONA trial of azacitidine + venetoclax versus azacitidine-+Placebo in patients with higher risk MDS with the primary endpoint of overall survival, what do you expect the results to be?”